• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Technology

Glooko adds chief strategy officer to chief medical officer’s title

May 19, 2025 By Sean Whooley

Glooko Logo

Glooko announced today that it expanded the position of Dr. Mark Clements to make him its chief medical and strategy officer. Clements became the Palo Alto, California-based diabetes management company’s fractional chief medical officer in 2016. He now steps into an expanded, full-time role designed to integrate Glooko’s clinical vision, product roadmap and data solutions. […]

Filed Under: Business/Financial News, Diabetes, Personnel, Technology Tagged With: glooko, Personnel Moves

Senseonics opens $50M public offering, $25M private placement with Abbott

May 15, 2025 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) announced today that it commenced an underwritten public offering of common stock worth $50 million. The long-term implantable continuous glucose monitor (CGM) maker expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of stock offered in the public offering. All shares to be […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Patient Monitoring, Technology Tagged With: Senseonics

Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

May 15, 2025 By Sean Whooley

Abbott FreeStyle Libre linked with fewer hospitalizations from heart complications in people with diabetes (1)

Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre continuous glucose monitoring (CGM) technology. Results from the REFLECT studies show that Libre CGM is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. Data demonstrated that CGM can help lessen the severity […]

Filed Under: Cardiovascular, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott

BD files patent infringement lawsuit against Baxter over infusion pump tech

May 13, 2025 By Sean Whooley

Baxter Novum IQ Infusion (BD alleges patent infringement against the system)

BD (NYSE:BDX) filed a lawsuit in a U.S. District Court alleging patent infringement by Baxter (NYSE:BAX) related to infusion pump technology. The company filed its complaint in the U.S. District Court for the District of Delaware on May 12, 2025. BD’s complaint singles out six specific patents: the “180,” “058,” “880,” “868,” “414,” and “703” […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Technology Tagged With: Baxter, BD

Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

May 13, 2025 By Sean Whooley

Tandem Diabetes Care updated logo

Tandem Diabetes Care (Nasdaq:TNDM) shared in an SEC filing that its Capillary Biomedical (CapBio) subsidiary won FDA 510(k) clearance for a new infusion set. The company won clearance for its SteadiSet Infusion Set, according to an SEC Form 8-K. It’s a wearable infusion set that delivers insulin from an insulin pump to the body. San Diego-based […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Technology Tagged With: capillarybiomedical, FDA, Tandem Diabetes Care

Glucotrack can proceed with long-term glucose monitor study in Australia

May 13, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

Dexcom promotes Jake Leach to president role

May 13, 2025 By Sean Whooley

Jake Leach Dexcom COO

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO. Leach originally took over as COO in 2022. He previously served as chief technology officer (CTO), starting in 2018. In that role, he led the company’s research, product development, product management and engineering departments. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel, Technology Tagged With: Dexcom, Personnel Moves

Roche invests $550M to make Indianapolis a CGM manufacturing hub

May 12, 2025 By Sean Whooley

Roche Accu-Chek SmartGuide CGM

Roche announced today that it plans to invest up to $550 million to expand its continuous glucose monitoring (CGM) site in the U.S. The company plans to invest in its Diagnostics site in Indianapolis in a project that runs through 2030. It expects to make the site — which serves as the North American headquarters […]

Filed Under: Business/Financial News, Diabetes, Diagnostics, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Roche, Roche Diabetes Care

Embecta to undergo further restructuring, lowers guidance amid tariff impact

May 9, 2025 By Sean Whooley

BD Diabetes Spinoff Embecta

Embecta (Nasdaq:EMBC) stock was down today after news of restructuring and mixed second-quarter results. Shares of EMBC were down more than 8% to $12.12 apiece near the close of trading today. While the company continues to work through the discontinuation of its insulin patch pump program — the plan for which it says is substantially […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology Tagged With: embecta

Insulet stock rises on Street-beating Q1, 29% sales uptick

May 9, 2025 By Sean Whooley

Insulet logo

Insulet’s (Nasdaq:PODD) stock soared more than 20% today on first-quarter results that exceeded the consensus forecast. Shares of PODD were trading at around $307 a share near the close of trading, the day after the company’s evening earnings report. The Acton, Massachusetts–based automated insulin delivery technology maker reported profits of $35.4 million. That equals 50¢ per […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Insulet

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 71
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS